NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.
The NOA-03 trial explored high-dose methotrexate alone in 37 patients with primary central nervous system lymphoma. The overall median survival was 25 months. After 4 years, the rate of leukoencephalopathy in patients surviving more than 12 months was 58% with and 10% without whole-brain radiotherap...
Main Authors: | Herrlinger, U, Küker, W, Uhl, M, Blaicher, H, Karnath, H, Kanz, L, Bamberg, M, Weller, M |
---|---|
Format: | Journal article |
Sprog: | English |
Udgivet: |
2005
|
Lignende værker
-
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.
af: Herrlinger, U, et al.
Udgivet: (2002) -
Primary central nervous system (CNS) lymphoma in immunocompetent patients.
af: Plasswilm, L, et al.
Udgivet: (2002) -
Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients.
af: Küker, W, et al.
Udgivet: (2005) -
Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
af: Küker, W, et al.
Udgivet: (2005) -
MRI features of primary central nervous system lymphomas at presentation.
af: Bühring, U, et al.
Udgivet: (2001)